Drugs / TT-10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04969315 | Jun 2023 → Jun 2026 overdue | castration-resistant prostate carcinoma, colorectal cancer, endometrial cancer, head and neck squamous cell carcinoma +3 | Portage Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04969315 ↗ |
| Known as | PORT-6 | “TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist” NCT04969315 ↗ |
| Route | Oral | “TT-10 orally administered BID” NCT04969315 ↗ |